4.61
price down icon2.12%   -0.10
after-market Handel nachbörslich: 4.51 -0.10 -2.17%
loading
Schlusskurs vom Vortag:
$4.71
Offen:
$4.54
24-Stunden-Volumen:
178.14K
Relative Volume:
0.39
Marktkapitalisierung:
$48.32M
Einnahmen:
$52.29M
Nettoeinkommen (Verlust:
$-73.52M
KGV:
-6.9848
EPS:
-0.66
Netto-Cashflow:
$-100.45M
1W Leistung:
-1.91%
1M Leistung:
-9.43%
6M Leistung:
-50.96%
1J Leistung:
-67.85%
1-Tages-Spanne:
Value
$4.4796
$4.71
1-Wochen-Bereich:
Value
$4.25
$4.99
52-Wochen-Spanne:
Value
$3.61
$14.93

Precision Biosciences Inc Stock (DTIL) Company Profile

Name
Firmenname
Precision Biosciences Inc
Name
Telefon
919-314-5512
Name
Adresse
302 EAST PETTIGREW STREET, DURHAM, NC
Name
Mitarbeiter
108
Name
Nächster Verdiensttermin
2024-11-04
Name
Neueste SEC-Einreichungen
Name
DTIL's Discussions on Twitter

Vergleichen Sie DTIL mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
DTIL
Precision Biosciences Inc
4.61 48.32M 52.29M -73.52M -100.45M -0.66
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
474.62 121.88B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
573.45 62.69B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
555.11 33.86B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
235.74 30.51B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
238.51 25.69B 3.81B -644.79M -669.77M -6.24

Precision Biosciences Inc Stock (DTIL) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-01-10 Hochstufung BMO Capital Markets Market Perform → Outperform
2024-04-30 Eingeleitet Guggenheim Buy
2022-06-17 Eingeleitet BMO Capital Markets Outperform
2022-06-09 Herabstufung William Blair Outperform → Mkt Perform
2020-07-27 Fortgesetzt BTIG Research Buy
2020-04-03 Herabstufung Goldman Buy → Neutral
2020-03-05 Eingeleitet Stifel Buy
2020-02-25 Eingeleitet William Blair Outperform
2019-08-09 Eingeleitet BTIG Research Buy
2019-07-16 Eingeleitet H.C. Wainwright Buy
2019-04-22 Eingeleitet Barclays Overweight
2019-04-22 Eingeleitet Goldman Buy
2019-04-22 Eingeleitet JP Morgan Overweight
2019-04-22 Eingeleitet Jefferies Buy
Alle ansehen

Precision Biosciences Inc Aktie (DTIL) Neueste Nachrichten

pulisher
07:38 AM

SEC Form PRE 14A filed by Precision BioSciences Inc. - Quantisnow

07:38 AM
pulisher
Apr 01, 2025

Precision BioSciences to Participate in the 24th Annual Needham Virtual Healthcare Conference - BioSpace

Apr 01, 2025
pulisher
Apr 01, 2025

Gene Editing Pioneer Precision BioSciences Reveals Latest ARCUS Platform Progress at Major Healthcare Conference - Stock Titan

Apr 01, 2025
pulisher
Mar 28, 2025

Precision Biosciences director Kevin Buehler buys $21,122 in stock - Investing.com Australia

Mar 28, 2025
pulisher
Mar 28, 2025

Precision Biosciences director Melinda Brown buys $8,735 in stock By Investing.com - Investing.com South Africa

Mar 28, 2025
pulisher
Mar 28, 2025

Precision Biosciences director Melinda Brown buys $8,735 in stock - Investing.com India

Mar 28, 2025
pulisher
Mar 28, 2025

Precision Biosciences director Kevin Buehler buys $21,122 in stock By Investing.com - Investing.com Canada

Mar 28, 2025
pulisher
Mar 27, 2025

Precision BioSciences (DTIL) Reports Q4 Loss, Misses Revenue Estimates - MSN

Mar 27, 2025
pulisher
Mar 27, 2025

Precision Biosciences director Germano Geno J purchases $17,225 in stock By Investing.com - Investing.com South Africa

Mar 27, 2025
pulisher
Mar 27, 2025

Precision Biosciences director Germano Geno J purchases $17,225 in stock - Investing.com India

Mar 27, 2025
pulisher
Mar 27, 2025

Precision BioSciences: Q4 Earnings Snapshot - Big Rapids Pioneer

Mar 27, 2025
pulisher
Mar 26, 2025

Precision BioSciences Reports Positive 2024 Financial Results - TipRanks

Mar 26, 2025
pulisher
Mar 26, 2025

Precision BioSciences Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 26, 2025
pulisher
Mar 26, 2025

PRECISION BIOSCIENCES Earnings Results: $DTIL Reports Quarterly Earnings - Nasdaq

Mar 26, 2025
pulisher
Mar 26, 2025

Precision Biosciences Reports Fourth Quarter And FY 2024 Results - MarketScreener

Mar 26, 2025
pulisher
Mar 26, 2025

Precision BioSciences Inc Q4 Sales Decline - Nasdaq

Mar 26, 2025
pulisher
Mar 26, 2025

Precision BioSciences Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Provides Business Update - Business Wire

Mar 26, 2025
pulisher
Mar 26, 2025

Breakthrough: Precision BioSciences' Gene Editing Therapy Delivers First Results in HBV Patients - Stock Titan

Mar 26, 2025
pulisher
Mar 25, 2025

Precision Biosciences CEO sells $5,359 in stock By Investing.com - Investing.com Australia

Mar 25, 2025
pulisher
Mar 25, 2025

Precision Biosciences CEO sells $5,359 in stock - Investing.com India

Mar 25, 2025
pulisher
Mar 25, 2025

Character Biosciences Raises $93 Million Series B to Advance Precision Medicine for Progressive Eye Diseases - Business Wire

Mar 25, 2025
pulisher
Mar 23, 2025

PRECISION BIOSCIENCES Earnings Preview: Recent $DTIL Insider Trading, Hedge Fund Activity, and More - Nasdaq

Mar 23, 2025
pulisher
Mar 23, 2025

Gene Editing Tools Market Growth Demand, Segment Analysis - openPR.com

Mar 23, 2025
pulisher
Mar 21, 2025

Precision BioSciences to Report Fourth Quarter and Fiscal Year 2024 Results on March 26, 2025 - BioSpace

Mar 21, 2025
pulisher
Mar 21, 2025

Precision BioSciences Presents Preclinical Safety and Efficacy Data Supporting Repeat Dosing of PBGENE-HBV With a Goal of Curing Chronic Hepatitis B at the Global Hepatitis Summit 2025 - Business Wire

Mar 21, 2025
pulisher
Mar 21, 2025

Precision BioSciences Earnings Call: Key ARCUS Gene Editing Platform Updates Expected March 26 - StockTitan

Mar 21, 2025
pulisher
Mar 20, 2025

Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - Business Wire

Mar 20, 2025
pulisher
Mar 20, 2025

H.C. Wainwright maintains $60 target on Precision BioSciences stock By Investing.com - Investing.com South Africa

Mar 20, 2025
pulisher
Mar 20, 2025

H.C. Wainwright maintains $60 target on Precision BioSciences stock - Investing.com

Mar 20, 2025
pulisher
Mar 20, 2025

Revolutionary Gene Therapy Achieves 99% Hepatitis B Virus EliminationKey Trial Updates - Stock Titan

Mar 20, 2025
pulisher
Mar 19, 2025

Precision Bio rises after gene editing data: BMO upgrades (update) - MSN

Mar 19, 2025
pulisher
Mar 19, 2025

Assessing Precision BioSciences: Insights From 4 Financial Analysts - Benzinga

Mar 19, 2025
pulisher
Mar 19, 2025

FDA Clears First-Ever In Vivo Gene-Editing Trial for Chronic Hepatitis B in the United States - CRISPR Medicine News

Mar 19, 2025
pulisher
Mar 19, 2025

Precision BioSciences Presents Preclinical Efficacy and Durability Data on PBGENE-DMD for the Treatment of Duchenne Muscular Dystrophy (DMD) at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference - 01Net

Mar 19, 2025
pulisher
Mar 19, 2025

Revolutionary DMD Treatment Restores 93% Muscle Strength, Could Help 60% of Patients - StockTitan

Mar 19, 2025
pulisher
Mar 17, 2025

Precision BioSciences' IND Application For PBGENE-HBV Gets FDA Clearance; Stock Climbs - RTTNews

Mar 17, 2025
pulisher
Mar 17, 2025

Precision Says its Investigational New Drug Application for Hepatitis B Treatment Gets US FDA's Clearance - MarketScreener

Mar 17, 2025
pulisher
Mar 17, 2025

Why Precision BioSciences Shares Are Trading Higher By Over 10%; Here Are 20 Stocks Moving Premarket - NewsBreak: Local News & Alerts

Mar 17, 2025
pulisher
Mar 17, 2025

Precision BioSciences Announces Clearance of Investigational New Drug Application by the U.S. FDA for First-in-Class PBGENE-HBV Designed to Eliminate Root Cause of Chronic Hepatitis B - BioSpace

Mar 17, 2025
pulisher
Mar 15, 2025

Precision & TG Therapeutics: Unlocking Value With ARCUS, BRIUMVI And Azer-Cel (NASDAQ:DTIL) - Seeking Alpha

Mar 15, 2025

Finanzdaten der Precision Biosciences Inc-Aktie (DTIL)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Precision Biosciences Inc-Aktie (DTIL) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
Brown Melinda
Director
Mar 26 '25
Buy
4.75
1,839
8,735
9,057
Germano Geno J
Director
Mar 25 '25
Buy
5.30
3,250
17,225
11,057
Amoroso Michael
President and CEO
Mar 24 '25
Sale
5.56
964
5,360
109,540
$60.58
price down icon 3.01%
$69.18
price down icon 5.66%
$17.36
price down icon 8.20%
$31.11
price down icon 2.14%
$88.05
price down icon 4.30%
biotechnology ONC
$238.51
price down icon 9.76%
Kapitalisierung:     |  Volumen (24h):